Clinical trials
Relapsed Hematologic Malignancy clinical trials
Below are recruiting relapsed hematologic malignancy clinical trials, each written for real people, not researchers. We’re tracking 117 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05417971Recruiting
Reduced-intensity chemo and radiation before a donor bone marrow transplant
This trial tests a lower-intensity chemotherapy and radiation plan before getting a bone marrow (stem cell) transplant from a related donor. It’s meant for people with blood cancers who are considered at higher risk of relapse with standard lower-intensity treatments.
Atlanta, GeorgiaAges 18 years+ - NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT05705570RecruitingPhase 1
CAR-T for CD19-positive relapsed or resistant blood cancers
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
São Paulo, São PauloAges 2–70 - NCT05302037RecruitingPhase 1
CAR T cell therapy for advanced cancers that can be targeted
This early-phase study tests a lab-made immune cell treatment that is designed to find and attack tumors that show a specific target on cancer cells. It is for adults with advanced cancers that have not responded well to at least two standard treatments.
SingaporeAges 21 years+ - NCT07284927RecruitingPhase 1
LV009 injection for blood and lymph cancers
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
Suzhou, JiangsuAges 18–70 - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT06879340RecruitingPhase 1
Testing a new CAR-T therapy for B-cell blood cancers
This study tests a new CAR-T cell therapy called DuoCAR20.19.22-D95 for people with certain blood cancers (like lymphoma and ALL) that have come back or haven't responded to multiple treatments. It aims to see if this therapy is safe and can help shrink or control the cancer.
Westwood, KansasAges 18 years+ - NCT05054257RecruitingPhase 1
CAR T19 for hard-to-treat blood cancers that have CD19
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
PragueAges 18–80 - NCT06622694RecruitingPhase 1
CD7 car-t cells for severe aplastic anemia
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05846750RecruitingPhase 2
Obinutuzumab plus lenalidomide for relapsed marginal zone lymphoma
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
Tianjin, TianAges 18 years+ - NCT06418776RecruitingPhase 3
Comparing treatments for AML that returns or doesn't respond
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
MoscowAges 18 years+ - NCT07249073RecruitingEarly Phase 1
Dual-target CAR-T for relapsed/refractory myeloma
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Birmingham, AlabamaAges 1–21 - NCT06996132RecruitingPhase 2
Combination treatment for aggressive B-cell lymphoma that has returned
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
TianjinAges 18–65 - NCT06244368RecruitingPhase 2
Chemo combo for relapsed aggressive lymphoma
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06880354RecruitingPhase 1
Dual-target CAR-T cells for relapsed or refractory AML
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
TianjinAges 18–70 - NCT07477912RecruitingPhase 1/Phase 2
BCMA-targeting CAR-T for relapsed/refractory multiple myeloma
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
MinskAges 18 years+ - NCT06265545Recruiting
Study for relapsed or hard-to-treat AML
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
TianjinAges Any age - NCT07162571Enrolling by invitationPhase 1/Phase 2
Engineered immune cells for advanced leukemia or lymphoma
This study tests a new type of immune therapy called CAR-T cells, which are made from your own blood cells to find and attack cancer. It is for adults with leukemia or lymphoma that has come back or is hard to treat.
MinskAges 18 years+ - NCT07862010RecruitingEarly Phase 1
Study of GI001 for B-cell lymphoma and leukemia that has returned or not responded
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
Yunnan, KunmingAges 18–75 - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years
Hear when a new Relapsed Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed hematologic malignancy?
- Yes. Clin2 currently lists 117 recruiting relapsed hematologic malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed hematologic malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed hematologic malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.